Clinical Trials Contract Manufacturing Immune Response 
pharmaphorum
SEPTEMBER 15, 2020
Humanigen is hoping for emergency use authorisation in the US for an antibody to treat severe COVID-19 before the end of 2020, and has teamed up with Swiss contract manufacturer Lonza to make sure it can meet demand. Roche meanwhile is continuing to trial its drug in combination with remdesivir.
The Pharma Data
DECEMBER 23, 2020
Additionally, Phase 1 clinical data found INO-4800 to have a favorable safety and tolerability profile with no serious adverse events reported; only six Grade 1 adverse events (AEs) were observed, primarily minor injection site reactions. ” Findings from the Phase 1 Clinical Trial. mg and 2.0
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JULY 21, 2021
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine. Procedures should be in place to avoid injury from fainting. The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients. myocarditis and pericarditis.
XTalks
FEBRUARY 27, 2024
Approximately 95 clinical trials evaluating TIL therapies have been registered globally. Amtagvi must be administered at an authorized treatment center (ATC) as part of a treatment regimen that includes lymphodepletion and a short course of high-dose Proleukin (aldesleukin or human recombinant IL-2) to kickstart the immune response.
The Pharma Data
JUNE 24, 2021
The production capacity has consistently grown due to continued enhancements to the vaccine’s supply chain, which include expanding existing facilities, adding more suppliers, and bringing on additional Pfizer/BioNTech sites and contract manufacturers around the world to produce the vaccine. BioNTech COVID-19 Vaccine. The Pfizer?BioNTech
Expert insights. Personalized for you.
97 
Let's personalize your content